Initiator Pharma A/S Market Cap ($13.30 Million)
Market Cap & Net Worth: Initiator Pharma A/S (INIT)
Initiator Pharma A/S market cap. Initiator Pharma A/S (ST:INIT) has a market capitalization of $13.30 Million (Skr123.56 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #26181 globally and #538 in its home market, demonstrating a -19.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Initiator Pharma A/S's stock price Skr1.81 by its total outstanding shares 68452892 (68.45 Million). Also see INIT cash flow conversion for how efficiently the company converts equity into cash flow.
Initiator Pharma A/S Market Cap History (2017–2026)
Initiator Pharma A/S market cap history from 2017 to 2026. Data shows change from $16.41 Million to $13.30 Million (-9.01% CAGR). Check Initiator Pharma A/S share price for real-time trading data and today's change.
Index Memberships
Initiator Pharma A/S is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.29 Billion | 0.09% | #132 of 281 |
Weight: Initiator Pharma A/S's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Initiator Pharma A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Initiator Pharma A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Initiator Pharma A/S (INIT) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of INIT by Market Capitalization
Companies near Initiator Pharma A/S in the global market cap rankings as of November 4, 2026. Also see how large is Initiator Pharma A/S's balance sheet for a full breakdown of the balance sheet.
Key companies related to Initiator Pharma A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Initiator Pharma A/S (2017–2026)
Market capitalization of Initiator Pharma A/S from 2017 to today. Between 2017 and today, Initiator Pharma A/S's market cap moved from $16.41 Million to $ 13.30 Million, with a yearly change of -9.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr13.30 Million | -39.02% |
| 2025 | Skr21.81 Million | -56.79% |
| 2024 | Skr50.46 Million | -25.87% |
| 2023 | Skr68.07 Million | +52.48% |
| 2022 | Skr44.64 Million | -25.55% |
| 2021 | Skr59.96 Million | +82.29% |
| 2020 | Skr32.90 Million | -39.55% |
| 2019 | Skr54.42 Million | +175.43% |
| 2018 | Skr19.76 Million | +20.42% |
| 2017 | Skr16.41 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Initiator Pharma A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.30 Million USD |
| MoneyControl | $13.30 Million USD |
| MarketWatch | $13.30 Million USD |
| marketcap.company | $13.30 Million USD |
| Reuters | $13.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to t… Read more